Lifeward Overview
Lifeward mission is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. The company is committed to delivering groundbreaking solutions that empower individuals to do what they love. As a global market leader in pioneering life-changing solutions, its portfolio features innovative products including the ReWalk Exoskeleton, the ReStore Exo-Suit, the MYOLYN FES bikes, and its newest addition, the AlterG Anti-Gravity systems.
Cumulative Funding Raised Over Time ($)
$4.3MApr 2019
$12.3MDec 2020
$52.3MFeb 2021
$52.3MJan 2007
$72.3MJan 2016
$77.3MJan 2025
$84.3MJul 2011
$101.3MJul 2014
$110.3MJul 2020
$111.5MJun 2013
$116.5MJun 2019
$136.4MMar 2018
$139.6MNov 2009
$172.1MSep 2021
Latest News
growth-positive
Lifeward unveils new anti-gravity rehab tech
Lifeward, formerly known as ReWalk Robotics, has launched the AlterG NEO anti-gravity treadmill, designed for physical rehabilitation. The treadmill utilizes differential air pressure (DAP) technology, making it more accessible to a wider range of rehab clinics and athletic training facilities. Lifeward acquired AlterG and its technology for approximately $19 million in August. The acquisition aims to expand Lifewards portfolio of neurorehabilitation products. CEO Larry Jasinski highlighted the benefits of the AlterG NEO in accelerating new solutions and expanding market reach. The technology helps users recover mobility, improve wellness, and enhance physical performance.
AcquisitionCustomers
growth-positive
Lifeward to Report First Quarter Financial Results on May 15, 2024
ReWalk Robotics Ltd. (DBA Lifeward), a leader in rehabilitation and recovery solutions, announced that it will release its first quarter 2024 financial results on May 15, 2024. CEO Larry Jasinski and CFO Michael Lawless will host a conference call and live webcast to discuss the results. Lifeward is known for its innovative products like the ReWalk Exoskeleton and AlterG Anti-Gravity systems, aimed at improving the lives of individuals with physical limitations. The call will be accessible via toll-free numbers and an online webcast, with an archived version available on the companys website.
Investment
growth-positive
ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward
ReWalk Robotics Ltd. has rebranded to Lifeward, reflecting its commitment to innovative technology for physical rehabilitation and recovery. The rebrand includes a new name, stock ticker, logo, website, and corporate messaging. The companys CEO, Larry Jasinski, stated that the transformation speaks to the broader goal of the company to elevate the standard of care in overcoming physical limitations and disabilities. The companys shares will begin trading under the new Nasdaq stock ticker: LFWD, starting from January 30, 2024.
Management Changes
growth-positive
7 ‘AgeTech’ Stocks to Profit From the Booming Longevity Market
The article discusses the growing field of AgeTech, technology aimed at improving the lives of senior citizens. It highlights seven companies that are making strides in this area: Best Buy, Apple, Microsoft, Teladoc, Abbott Laboratories, Cigna, and ReWalk Robotics. Best Buys Health unit provides a service to help seniors stay connected and safe. Apples devices, such as the Apple Watch, have features that can be beneficial to seniors. Microsoft offers accessibility tools for mental health. Teladoc provides telehealth services, which can be especially useful for seniors with reduced mobility. Abbott Laboratories is known for its diabetes management system, which can be beneficial to seniors as the risk of diabetes increases with age. Cigna offers Medicare Advantage plans with benefits like telehealth access and chronic disease management programs. ReWalk Robotics develops exoskeletons to help individuals with spinal cord injuries regain walking ability.
CustomersExpand
growth-positive
Sidoti Events, LLC's Virtual January Micro-Cap Conference
Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has announced the presentation schedule for its two-day January Micro-Cap Conference taking place on January 17-18, 2024. The conference will feature presentations from a variety of micro-cap companies. Sidoti Events was formed in 2023 to focus on the companys growing conference business and to serve the needs of presenters and attendees. The company benefits from Sidotis small- and microcap-focused nationwide sales force, which has connections with 1,500 institutional relationships in North America.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $249.72M |
| Last funding | $5M |
| Stage | Public |
| Rounds | 20 |
| Investors | 11 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | golifeward.com/ |
Locations
HaTnufa St 3, Yokne'am Illit, Israel
Leipziger Pl. 15 10117 Berlin, Germany
200 Donald Lynch Blvd Marlborough, MA 01752, USA
Photos & Videos
6 item(s)
Lifeward Business
Business models
B2B, B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareDigital Accessibility SolutionsMedical DevicesAssistive DevicesTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsCore Technology
Semiconductors & ElectronicsWearablesCommunicationsIOTMachinery & RoboticsExoskeletonSensingTags (14)
wearabledisabilitiesmedical-devicesiotorthopedicsrehabilitationsensorsassistive-devicesphysiotherapystroketelehealthroboticsdigital-healthcarereal-timeGeographic Markets
AustriaFranceJapanGermanyItalyIsraelUnited StatesEuropeUnited KingdomChinaLifeward Financials
$249.72M
Total funding
Undisclosed
Capital raised
$5M
Last funding
Public
Funding stage
20
Total rounds
11
Investors
Cumulative Funding Raised Over Time ($)
$4.3MApr 2019
$12.3MDec 2020
$52.3MFeb 2021
$52.3MJan 2007
$72.3MJan 2016
$77.3MJan 2025
$84.3MJul 2011
$101.3MJul 2014
$110.3MJul 2020
$111.5MJun 2013
$116.5MJun 2019
$136.4MMar 2018
$139.6MNov 2009
$172.1MSep 2021
Private Equity Funding
PIPE
Jan 2025
$5M
PIPE
Sep 2021
$32.5M
Undisclosed Investor(s)
PIPE
Feb 2021
$40M
Undisclosed Investor(s)
PIPE
Dec 2020
$8M
Undisclosed Investor(s)
PIPE
Jul 2020
$9M
Undisclosed Investor(s)
PIPE
Jun 2019
$5M
Undisclosed Investor(s)
PIPE
Apr 2019
$4.25M
Undisclosed Investor(s)
PIPE
Mar 2018
$20M
Timwell Corporation Limited (Hong Kong)
Convertible Debt
Jan 2016
$20M
Kreos Capital
E Round
Jul 2014
$17M
OurCrowd (Lead)
,
Yaskawa, Previz Ventures, Bearing Capital
D Round
Jun 2013
$1.2M
OurCrowd
C Round
Jul 2011
$7M
SCP Vitalife, Technion, Ratio Technologies
Undisclosed Round
Nov 2009
$3.1M
SCP Vitalife, Ratio Technologies
Undisclosed Round
Jan 2007
Undisclosed
Shavit Capital Fund
Public Offering / Exit
POEvent
Feb 2020
Undisclosed
POEvent
Jun 2019
Undisclosed
POEvent
Feb 2019
Undisclosed
POEvent
Nov 2018
Undisclosed
POEvent
Nov 2017
Undisclosed
POEvent
Sep 2014
Undisclosed
Mergers & Acquisitions
MNAEvent
Aug 2023
$19M
Lifeward Lifecycle
Cumulative Funding Raised Over Time
$4.3MApr 2019
$12.3MDec 2020
$52.3MFeb 2021
$52.3MJan 2007
$72.3MJan 2016
$77.3MJan 2025
$84.3MJul 2011
$101.3MJul 2014
$110.3MJul 2020
$111.5MJun 2013
$116.5MJun 2019
$136.4MMar 2018
$139.6MNov 2009
$172.1MSep 2021
All Events
PIPE
Jan 2025
$5M
PIPE
Sep 2021
$32.5M
Undisclosed Investor(s)
PIPE
Feb 2021
$40M
Undisclosed Investor(s)
PIPE
Dec 2020
$8M
Undisclosed Investor(s)
PIPE
Jul 2020
$9M
Undisclosed Investor(s)
PIPE
Jun 2019
$5M
Undisclosed Investor(s)
PIPE
Apr 2019
$4.25M
Undisclosed Investor(s)
PIPE
Mar 2018
$20M
Timwell Corporation Limited (Hong Kong)
Convertible Debt
Jan 2016
$20M
Kreos Capital
E Round
Jul 2014
$17M
OurCrowd (Lead)
,
Yaskawa, Previz Ventures, Bearing Capital
D Round
Jun 2013
$1.2M
OurCrowd
C Round
Jul 2011
$7M
SCP Vitalife, Technion, Ratio Technologies
Undisclosed Round
Nov 2009
$3.1M
SCP Vitalife, Ratio Technologies
Undisclosed Round
Jan 2007
Undisclosed
Shavit Capital Fund
POEvent
Feb 2020
Undisclosed
POEvent
Jun 2019
Undisclosed
POEvent
Feb 2019
Undisclosed
POEvent
Nov 2018
Undisclosed
POEvent
Nov 2017
Undisclosed
POEvent
Sep 2014
Undisclosed
MNAEvent
Aug 2023
$19M
Lifeward News
102 articles
growth-positive
Lifeward unveils new anti-gravity rehab tech
Lifeward, formerly known as ReWalk Robotics, has launched the AlterG NEO anti-gravity treadmill, designed for physical rehabilitation. The treadmill utilizes differential air pressure (DAP) technology, making it more accessible to a wider range of rehab clinics and athletic training facilities. Lifeward acquired AlterG and its technology for approximately $19 million in August. The acquisition aims to expand Lifewards portfolio of neurorehabilitation products. CEO Larry Jasinski highlighted the benefits of the AlterG NEO in accelerating new solutions and expanding market reach. The technology helps users recover mobility, improve wellness, and enhance physical performance.
AcquisitionCustomers
growth-positive
Lifeward to Report First Quarter Financial Results on May 15, 2024
ReWalk Robotics Ltd. (DBA Lifeward), a leader in rehabilitation and recovery solutions, announced that it will release its first quarter 2024 financial results on May 15, 2024. CEO Larry Jasinski and CFO Michael Lawless will host a conference call and live webcast to discuss the results. Lifeward is known for its innovative products like the ReWalk Exoskeleton and AlterG Anti-Gravity systems, aimed at improving the lives of individuals with physical limitations. The call will be accessible via toll-free numbers and an online webcast, with an archived version available on the companys website.
Investment
growth-positive
ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward
ReWalk Robotics Ltd. has rebranded to Lifeward, reflecting its commitment to innovative technology for physical rehabilitation and recovery. The rebrand includes a new name, stock ticker, logo, website, and corporate messaging. The companys CEO, Larry Jasinski, stated that the transformation speaks to the broader goal of the company to elevate the standard of care in overcoming physical limitations and disabilities. The companys shares will begin trading under the new Nasdaq stock ticker: LFWD, starting from January 30, 2024.
Management Changes
growth-positive
7 ‘AgeTech’ Stocks to Profit From the Booming Longevity Market
The article discusses the growing field of AgeTech, technology aimed at improving the lives of senior citizens. It highlights seven companies that are making strides in this area: Best Buy, Apple, Microsoft, Teladoc, Abbott Laboratories, Cigna, and ReWalk Robotics. Best Buys Health unit provides a service to help seniors stay connected and safe. Apples devices, such as the Apple Watch, have features that can be beneficial to seniors. Microsoft offers accessibility tools for mental health. Teladoc provides telehealth services, which can be especially useful for seniors with reduced mobility. Abbott Laboratories is known for its diabetes management system, which can be beneficial to seniors as the risk of diabetes increases with age. Cigna offers Medicare Advantage plans with benefits like telehealth access and chronic disease management programs. ReWalk Robotics develops exoskeletons to help individuals with spinal cord injuries regain walking ability.
CustomersExpand
growth-positive
Sidoti Events, LLC's Virtual January Micro-Cap Conference
Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has announced the presentation schedule for its two-day January Micro-Cap Conference taking place on January 17-18, 2024. The conference will feature presentations from a variety of micro-cap companies. Sidoti Events was formed in 2023 to focus on the companys growing conference business and to serve the needs of presenters and attendees. The company benefits from Sidotis small- and microcap-focused nationwide sales force, which has connections with 1,500 institutional relationships in North America.
CustomersPartners
Growth-Negative
ReWalk Robotics (NASDAQ:RWLK investor five-year losses grow to 82% as the stock sheds US$10m this past week
ReWalk Robotics Ltd. has seen a 54% rebound in its stock over the last month, but this does not negate the fact that the companys returns over the last five years have been disappointing, with the share price falling 82% over that period. The company is currently unprofitable and its revenue growth over five years is a mere 2.3% per year. Despite recent improvements, investor sentiment for ReWalk Robotics remains negative. The companys total shareholder return over the last year is 25%, which is a significant improvement compared to the TSR loss of 13% per year over five years.
Public Trading
Growth-Positive
ReWalk Robotics Expands Direct Sales Coverage to Canada
ReWalk Robotics Ltd., a provider of innovative technologies for individuals with neurological conditions, is expanding its direct sales coverage to Canada. This expansion is a result of the integration of the former ReWalk and AlterG commercial teams following a recent acquisition. The company believes that the Canadian market for Anti-Gravity systems has been underserved and anticipates that the expanded direct sales presence will allow more effective market penetration. The integration of AlterG and ReWalk is expected to result in faster growth and a leaner cost structure.
ExpandAcquisition
Growth-Positive
ReWalk Robotics Ltd. to Present at Sidoti Virtual Investor Conference on January 17
ReWalk Robotics Ltd. has announced that its CEO, Larry Jasinski, and CFO, Mike Lawless, will present an overview of the company and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference on January 17-18, 2024. The company, which designs, develops, and commercializes technologies to aid mobility in individuals with neurological conditions, recently expanded its portfolio with the acquisition of AlterG, Inc., adding anti-gravity systems to its product range. ReWalk has operations in the United States, Israel, and Germany.
growth-positive
First ReWalk Personal Exoskeleton Claim Paid by Medicare
ReWalk Robotics Ltd. has received its first payment from Noridian Healthcare Solutions, a Medicare Administrative Contractor, for its ReWalk Personal Exoskeleton. This marks the first-ever claim submitted for a ReWalk Personal Exoskeleton device, reflecting Medicares acknowledgement of the device as medically necessary for eligible beneficiaries with spinal cord injury. The payment represents a significant achievement for the paralyzed community and underscores the medical necessity of the ReWalk Exoskeleton. The company looks forward to continuing its work with Medicare following the implementation of the 2024 Home Health Rule.
CustomersPartners
growth-positive
ReWalk Robotics CEO Issues Year-End 2023 Open Letter to Shareholders and Provides 2024 Commercial and Operational Priorities
ReWalk Robotics Ltd. has issued an open letter detailing its achievements in 2023 and plans for 2024. The company made significant progress with the Centers for Medicare & Medicaid Services to finalize a new benefit category and establish a reimbursement rate for its ReWalk Exoskeleton. It also acquired and integrated the AlterG business, expanding its portfolio of innovative rehabilitation solutions. The company plans to continue its growth in 2024, with a focus on expanding access to its technology, integrating ReWalk and AlterG, and advancing new innovations to market. It also implemented a cost structure optimization plan, which included a 15% reduction in force at the end of 2023.
AcquisitionExpandManagement ChangesLayoffs
Growth-Negative
We Think ReWalk Robotics (NASDAQ:RWLK) Needs To Drive Business Growth Carefully
ReWalk Robotics, a software-as-a-service business, is increasing its cash burn by 21% in the last year, raising concerns among shareholders. Despite this, the companys operating revenue improved by 100% over the same period. The company had a cash runway of approximately 19 months from September 2023, with zero debt and cash worth US$33m. However, its cash burn relative to its market cap is high, which could lead to significant share dilution if the company needs to raise more cash to fund growth.
Investment
growth-positive
ReWalk Robotics Presents on Personal Exoskeleton Pricing at Medicare Public Meeting
ReWalk Robotics Ltd. presented at the Healthcare Common Procedure Coding System (HCPCS) public meeting on November 29, 2023, and provided feedback to the Centers for Medicare & Medicaid Services (CMS) regarding the preliminary payment determination for the code describing the ReWalk Personal Exoskeleton. The company supports the gap-filling pricing method proposed by CMS and provided updated pricing information for the current ReWalk Personal Exoskeleton. CMS is expected to review the additional information submitted by ReWalk and issue a final payment determination in February 2024.
CustomersPartners
growth-positive
Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth
The article discusses seven penny stocks that are poised for growth. These include PowerFleet, a provider of wireless IoT and M2M solutions; Perpetua Resources, a mining specialist; Synchronoss Technologies, a provider of white label cloud, messaging, digital and network management solutions; Heron Therapeutics, a biotech firm focusing on developing novel solutions for patients with unmet needs; Rewalk Robotics, a company that provides exo-suits to help people regain mobility; ClearSign Technologies, a company that provides cost and energy-efficient solutions for the refining, petrochemical and boiler industries; and AC Immune, a biopharmaceutical firm focusing on pioneering new ways to diagnose, treat and prevent neurodegeneration.
Investment
growth-positive
ReWalk Robotics Demonstrates AI Autonomous Decision Making in Next Generation Exoskeleton Prototype
ReWalk Robotics Ltd. has successfully demonstrated a proof-of-concept next-generation exoskeleton. The project was funded by a grant from the Israeli Technology Innovation Consortium and is part of the Israel Innovation Authority’s MAGNET incentive program. The new exoskeleton integrates advanced sensing technologies and artificial intelligence to enable autonomous decision making. The company is part of the Human Robot Interaction Consortium and collaborates with several universities to develop advanced technologies aimed at improving the human-exoskeleton interaction.
InvestmentPartnersExpand
growth-positive
7 Cheap Stocks to Buy Now if You Have $100 to Spend: November Edition
The article discusses seven companies with stocks under $100 that are considered good investments. Ford is highlighted for its robust growth potential and 7.21% dividend yield. Kinross Gold is noted for its attractive forward price-earnings ratio and dividend yield. United Microelectronics Corp is recognized for its global footprint and growth despite challenges. Nio is mentioned for its recovery from near bankruptcy and promising signs of growth. Destination XL is considered a unique opportunity in the retail sector. SoundHound AI is praised for its innovative solutions and collaborations with industry giants. Finally, ReWalk Robotics is commended for its pioneering work in wearable robotic exoskeletons and solid financial position.
InvestmentManagement ChangesLayoffs
growth-positive
ReWalk Robotics Reports Third Quarter 2023 Financial Results
ReWalk Robotics Ltd. has announced its financial results for Q3 2023, revealing a record quarterly revenue of $4.4 million. This represents a significant increase from the $0.9 million reported in Q3 2022. The company also highlighted the successful completion of its acquisition of AlterG, Inc., and the significant progress made in integrating the two companies. Furthermore, ReWalk has made major advancements in its efforts to attain Medicare payment coverage of exoskeletons. The companys CEO, Larry Jasinski, stated that the past three months have been pivotal in building ReWalks foundation for growth and profitability.
AcquisitionCustomers
growth-positive
New Bill Facilitates Veteran Access to Powered Exoskeletons
ReWalk Robotics Ltd., a provider of innovative technologies for individuals with neurological conditions, has praised new legislation to be introduced in the U.S. House of Representatives. The Veterans Spinal Trauma Access to New Devices (STAND) Act will enhance opportunities for clinically-eligible U.S. Veterans to gain access to powered exoskeletons. The Act also ensures the U.S Department of Veterans’ Affairs (VA) delivers the technology in a routine and timely manner. The VA estimates that approximately 42,000 individuals with spinal cord injuries are U.S. Veterans, of which the VA provides annual care to more than 27,000 individuals.
CustomersPartners
Neutral
ReWalk Robotics to Report Third Quarter 2023 Financial Results on November 14, 2023
ReWalk Robotics Ltd. has announced that it will release its third quarter 2023 financial results on November 14, 2023. The companys CEO, Larry Jasinski, and CFO, Michael Lawless, will host a conference call and live webcast to discuss the results. ReWalk Robotics is a medical device company that designs and develops technologies to improve mobility and wellness for individuals with neurological conditions. The company recently acquired AlterG, Inc., adding anti-gravity systems to its product portfolio.
Growth-Positive
ReWalk Robotics to Discuss Medicare’s Preliminary Payment Determination for ReWalk Personal Exoskeleton
ReWalk Robotics Ltd. has announced a conference call scheduled for November 8, 2023, to discuss Medicare’s preliminary payment determination for the ReWalk Personal Exoskeleton. The Centers for Medicare & Medicaid Services released an agenda for a meeting on November 29, 2023, which includes an item to discuss the Medicare payment determination for the ReWalk Personal Prosthetic Exoskeleton system and provides a preliminary payment determination of $94,617. The conference call will be hosted by Larry Jasinski, CEO, Jeannine Lynch, VP of Market Access and Strategy, and Mike Lawless, CFO.
Investment
Growth-Positive
In Historic Move, Medicare Proposes Preliminary Reimbursement Level for ReWalk Personal Exoskeleton
ReWalk Robotics Ltd, a provider of innovative technologies for individuals with neurological conditions, has announced that the Centers for Medicare & Medicaid Services (CMS) has included the ReWalk Personal Prosthetic Exoskeleton system in the agenda for the upcoming Healthcare Common Procedure Coding System (HCPCS) meeting on November 29, 2023. CMS has provided a preliminary payment determination of $94,617 for the system. The inclusion of the ReWalk Exoskeleton within the upcoming HCPCS agenda and the proposed preliminary pricing is a significant step forward in ReWalks efforts to ensure broader access to exoskeletons for the spinal cord injury community with Medicare coverage.
CustomersPartners
Growth-Positive
In Historic Move, Medicare Proposes Preliminary Reimbursement Level for ReWalk Personal Exoskeleton
ReWalk Robotics Ltd., a provider of innovative technologies for individuals with neurological conditions, has announced that the Centers for Medicare & Medicaid Services (CMS) has included the ReWalk Personal Prosthetic Exoskeleton system in the agenda for the upcoming Healthcare Common Procedure Coding System (HCPCS) meeting. The CMS has provided a preliminary payment determination of $94,617 for the system. The company is encouraged by the process used by CMS to determine its preliminary pricing and is looking forward to working with CMS at the upcoming HCPCS meeting.
CustomersPartners
growth-positive
Medicare Coverage Solidified for ReWalk Personal Exoskeleton
ReWalk Robotics Ltd. has expressed its appreciation to the Centers for Medicare & Medicaid Services (CMS) for finalizing the Calendar Year 2024 Home Health Prospective Payment System Rule CMS-1780, which includes exoskeletons in the Medicare brace benefit category. The rule, which will go into effect on January 1, 2024, will expedite coverage and payment for newer technology and powered devices, potentially providing faster access to these new healthcare technologies for Medicare beneficiaries. This is a major milestone for ReWalk in its efforts to expand access to its life-changing technology for the spinal cord injury community with Medicare coverage.
CustomersExpand
Growth-positive
The 3 Best Penny Stocks to Buy in November
The article discusses three penny stocks that could potentially yield high returns for investors. These include Destination XL (DXLG), a retail company focused on mens big and tall apparel, Broadwind (BWEN), an industrial services provider with a significant presence in the renewable energy sector, and ReWalk Robotics (RWLK), a company that develops wearable robotic exoskeletons for people with spinal cord injuries. The author advises extreme caution when investing in penny stocks due to their high risk and volatility.
Investment
ReWalk Robotics Exhibits at the GITEX GLOBAL Intelligent Connectivity / AI Pavilion
Neutral
ReWalk Robotics Offers Thanks to Former Director for His Loyal Service and Valuable Contributions
ReWalk Robotics Ltd. has announced that Yohanan Engelhardt will no longer serve as a director on the companys board. Engelhardt had served as chairman of the audit committee for over five years. Jeff Dykan, Chairman of the Board of ReWalk, thanked Engelhardt for his contributions to the company. ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions.
Management Changes
Shareholders May Not Be So Generous With ReWalk Robotics Ltd.'s (NASDAQ:RWLK) CEO Compensation And Here's Why
Growth-Positive
ReWalk Robotics Ltd. to Present Virtually at H.C. Wainwright 25th Annual Global Investment Conference
ReWalk Robotics Ltd. has announced that its CEO, Larry Jasinski, will present and host one-on-one meetings with investors at the H.C. Wainwright 25th Annual Global Investment Conference, which will be held virtually from September 11-13, 2023. The presentation will be available via webcast and will be accessible on the companys website for 90 days. ReWalk Robotics is a medical device company that designs and develops technologies to enhance mobility and wellness for individuals with neurological conditions.
Investment
growth-negative
ReWalk Robotics Announces Additional Change to Board of Directors
ReWalk Robotics Ltd., a provider of technologies for mobility and wellness in rehabilitation for individuals with neurological conditions, announced that Yasushi Ichiki intends to resign from the Board of Directors following the Company’s 2023 Annual Meeting of Shareholders on September 13, 2023. His resignation, along with the previous announcement of two directors not seeking re-election, will reduce the size of the Company’s Board to seven.
Management Changes
growth-positive
Israel's ReWalk snaps up AlterG for $19 million in profitability push
ReWalk Robotics, an Israeli company that develops robotic exoskeleton systems, has acquired California-based AlterG for $19 million. The acquisition is expected to expand ReWalks rehabilitation technology offerings and boost its revenue growth. AlterG is known for its anti-gravity treadmill, which is used for physical and neurological rehabilitation. The combined company is projected to generate a trailing 12-month revenue of about $26 million. ReWalk Robotics was founded in 2001 and its exoskeleton system was the first to be cleared by the US FDA for rehabilitation and personal use.
Acquisition
Growth-Negative
ReWalk Robotics (RWLK) Reports Q2 Loss, Tops Revenue Estimates
ReWalk Robotics reported a quarterly loss of $0.05 per share, which is better than the Zacks Consensus Estimate of a loss of $0.07. This is also an improvement from the loss of $0.07 per share a year ago. The company, which makes wearable robotic exoskeletons to help paralyzed patients walk, posted revenues of $1.34 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 0.15%. However, ReWalk shares have lost about 5.5% since the beginning of the year, underperforming the market.
InvestmentPublic Trading
ReWalk Robotics Reports Second Quarter 2023 Financial Results
growth-positive
ReWalk Robotics Announces Closing of Acquisition of AlterG
ReWalk Robotics Ltd., a provider of innovative technologies for individuals with neurological conditions, has announced the completion of its acquisition of AlterG, Inc., a leading provider of Anti-Gravity systems for use in physical and neurological rehabilitation. The purchase price was approximately $19 million in cash. As part of the transaction, Charles Remsberg, former CEO of AlterG, was appointed as Chief Sales Officer of ReWalk. The acquisition is expected to expand access for patients to innovative rehabilitation technologies.
AcquisitionManagement Changes
growth-positive
How ReWalk's $19M acquisition could help it turn a profit after 22 years
ReWalk, a Marlborough-based company specializing in personal exoskeletons, has announced a $19 million acquisition of AlterG, a company from Fremont, California known for its bionic legs and anti-gravity physical rehabilitation systems. This acquisition is a strategic move aimed at helping ReWalk turn a profit after 22 years by inheriting AlterGs salesforce. The acquisition is also in preparation for a potential Medicare and Medicaid reimbursement later this year.
Acquisition
growth-positive
ReWalk Robotics to Acquire AlterG; Acquisition Builds Commercial Scale and Accelerates Path to Profitability
ReWalk Robotics Ltd. has announced its acquisition of AlterG, Inc., a leading innovator and provider of Anti-Gravity systems for use in physical and neurological rehabilitation. The acquisition is expected to expand ReWalks customer-facing capabilities and advance future growth opportunities. The transaction is projected to increase revenue growth, improve operating margin, and reduce the cash burn rate. The cash purchase price is approximately $19 million, with the closing anticipated to occur on August 11, 2023. AlterG generated revenue of $20 million in fiscal year 2022 with a positive operating profit.
Acquisition
Neutral
ReWalk Robotics to Report Second Quarter Financial Results on August 11, 2023
ReWalk Robotics Ltd. has announced that it will release its second quarter 2023 financial results on August 11, 2023. The companys CEO, Larry Jasinski, and CFO, Michael Lawless, will host a conference call and live webcast to discuss the results. ReWalk Robotics is a medical device company that designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions.
growth-negative
ReWalk Robotics Announces Planned Changes to Board of Directors
ReWalk Robotics Ltd. announced that two members of the Board of Directors, Arik Dan and Wayne Weisman, will not be seeking re-election when their terms expire at the next Annual Meeting of Shareholders. The company does not plan to nominate any replacement candidates, reducing the size of the Board from ten to eight directors. This decision is part of the companys commitment to shrink the Board while maintaining essential skills and experience.
Management Changes
Growth-Positive
ReWalk Robotics Ltd. to Present at the Emerging Growth Conference on July 12
ReWalk Robotics Ltd. announced that its CEO, Larry Jasinski, will present at the Emerging Growth Conference on July 12, 2023. The presentation will be virtual and interested investors can register online to receive updates. An archived version of the presentation will be made available on the companys website after the event. ReWalk Robotics is a medical device company that designs and develops technologies to improve mobility and wellness for individuals with neurological conditions.
Management Changes
growth-positive
Presenting on the Emerging Growth Conference on July 12 & 13 Register Now
EmergingGrowth.com, a leading independent small cap media portal, has announced the schedule for the 60th Emerging Growth Conference on July 12 & 13, 2023. The conference identifies companies in various growth sectors that have strong management teams, innovative products & services, focused strategies, and the potential for long-term growth. Companies such as Spire Global, Inc., OHB SE, ReWalk Robotics Ltd., and many others will be presenting at the conference. The conference serves as a platform for public companies to engage with the investment community.
CustomersPartners
growth-positive
ReWalk Robotics Applauds Medicare Proposal to Include Personal Exoskeletons in a Medicare Benefit Category to be Paid on a Lump Sum Basis
ReWalk Robotics applauds the Centers for Medicare & Medicaid Services proposal to include personal exoskeletons in the Medicare benefit category for braces. The proposed rule would establish a new regulatory definition of brace and include exoskeletons like the ReWalk Personal Exoskeleton in this definition. This would expedite coverage and payment for personal exoskeletons, allowing paralyzed patients to stand and walk again. ReWalk is collaborating with stakeholders during the public comment period to support the proposal. The finalization of a clear benefit category for proposed exoskeletons is expected in early November.
Customers
growth-negative
We Think ReWalk Robotics (NASDAQ:RWLK) Needs To Drive Business Growth Carefully
The article discusses ReWalk Robotics cash burn and its impact on the company. It mentions that the company has a cash runway of about 3.5 years from March 2023. However, it also highlights that the companys cash burn has increased by 24% in the last year, which is concerning. The article suggests that if the company wants to raise more cash for growth, it may need to issue shares, which could hurt shareholders returns through dilution. Overall, while the cash burn is not seen as particularly problematic, shareholders should monitor it closely. The article does not mention any specific investors or partners.
Investment
ReWalk Robotics (RWLK) Reports Q1 Loss, Misses Revenue Estimates
growth-positive
ReWalk Robotics Reports First Quarter 2023 Financial Results
ReWalk Robotics Ltd. has reported its financial results for Q1 2023, showing a 40% increase in total revenue compared to Q1 2022. The companys gross margin also increased by 16 percentage points. The companys ReWalk Personal Exoskeleton technology received FDA clearance for use on stairs and curbs in March 2023. The company also made its first Medicare claim submission, setting the parameters for ten additional planned submissions in Q2. The companys total revenue was $1.2 million in Q1 2023, compared to $0.9 million in Q1 2022.
CustomersInvestment
growth-negative
ViewRay (VRAY) Reports Q1 Loss, Misses Revenue Estimates
ViewRay reported a quarterly loss of $0.16 per share, missing the Zacks Consensus Estimate. The companys revenues also fell short of expectations. ViewRay shares have declined significantly this year. The article discusses the companys earnings outlook and the impact of industry performance on the stock. ReWalk Robotics, a competitor in the same industry, is yet to report its results.
CustomersInvestment
growth-positive
Sidoti's Micro-Cap Virtual May Conference
Sidoti & Company, LLC has announced the schedule for its two-day May Micro-cap Conference taking place on May 10-11, 2023. The conference will feature presentations from a variety of small and microcap companies, including Polypid Ltd., HydroGraph Clean Power Inc., Orange Polska, AnPac Bio-Medical Science, InfuSystem Holdings Inc., Olympic Steel, Inc., and many others. Sidoti & Company is a leading provider of independent securities research focused on small and microcap companies and the institutions that invest in their securities.
Customers
Artivion (AORT) Q1 Earnings and Revenues Beat Estimates
ReWalk Robotics to Provide First U.S. Demonstrations of Groundbreaking Stairs-Enabled Exoskeleton Technology
ReWalk Robotics Ltd. to Report First Quarter Financial Results on May 11, 2023
growth-positive
ReWalk Robotics Ltd. to Present at Sidoti Virtual Investor Conference on May 10
ReWalk Robotics Ltd. announced that its CEO and CFO will present and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference. The company has also created a new investor relations presentation and posted it on its website. ReWalk Robotics is a medical device company that designs and develops technologies for individuals with neurological conditions. The company aims to improve mobility and wellness in rehabilitation and daily life. ReWalk has operations in the U.S., Israel, and Germany.
InvestmentPublic Trading
Advancement in ReWalk Technology Achieves FDA Clearance as Only Personal Exoskeleton to Enable Use on Stairs and Curbs
ReWalk Robotics Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
ReWalk Robotics (RWLK) Reports Q4 Loss, Tops Revenue Estimates
ReWalk Robotics Reports Fourth Quarter and Full Year 2022 Financial Results
ReWalk Robotics to Report Fourth Quarter and Fiscal Year-End 2022 Financial Results on February 23, 2023
Will ReWalk Robotics (NASDAQ:RWLK) Spend Its Cash Wisely?
growth-positive
“Modern Miracles”: ReWalk Technology Showcased at the Hanukkah Celebration Hosted by the Embassy of the State of Israel to Belgium and Luxembourg in Antwerp
ReWalk Robotics, Ltd., a manufacturer of robotic medical devices for individuals with lower limb disabilities, presented its technology at an event hosted by the Embassy of the State of Israel to Belgium and Luxembourg. The event was attended by high-ranked members of Belgium’s political and social life. The companys exoskeleton technology was showcased by Mr. Jacques Depuydt, the first ReWalker in Belgium, who has been using the device since 2013. The company aims to increase awareness of the benefits of ReWalk and expand access to its technology.
Customers
ReWalk Announces Extension of Share Repurchase Program
growth-positive
13 Best Robotics Stocks To Buy Now
The article discusses the growth of the global robotics market, which was worth $27.73 billion in 2020 and is forecasted to reach $74.1 billion by 2026. The COVID-19 pandemic has accelerated the growth of the robotics industry, with increased demand for service robots and delivery robots. The industrial robotics market is expected to grow from $15.7 billion in 2022 to $30.8 billion by 2027. The article highlights Nauticus Robotics, Inc., which debuted as a publicly traded company in September 2022 after a SPAC merger with New York-based CleanTech Acquisition Corp. The company is aiming to capitalize on market interest in companies working to reduce water pollution.
InvestmentPublic Trading
Germany’s second largest health insurer withdraws appeal with Federal Social Court, accepts prior ruling of exoskeletons as direct disability compensation
ReWalk Robotics (RWLK) Reports Q3 Loss, Lags Revenue Estimates
ReWalk Robotics Reports Third Quarter 2022 Financial Results
Neutral
ReWalk Robotics to Report Third Quarter 2022 Financial Results on November 7, 2022
ReWalk Robotics Ltd. has announced that it will release its third quarter 2022 financial results on November 7, 2022. The companys CEO, Larry Jasinski, and CFO, Michael Lawless, will host a conference call to discuss the results. ReWalk Robotics develops, manufactures, and markets wearable robotic exoskeletons for individuals with lower limb disabilities due to spinal cord injury or stroke.
Public Trading
growth-positive
ReWalk Takes Another Step Toward Medicare Coverage
ReWalk Robotics Ltd. will begin submitting Medicare cases for the ReWalk exoskeleton following CMSs announcement affirming coverage and reimbursement. The company is actively engaged with CMS in evaluating advanced technologies like exoskeletons. ReWalk aims to expand access to its exoskeletons for Medicare beneficiaries with spinal cord injuries, as studies have shown significant health benefits from using the technology. The company will advocate for Medicare to provide these devices to beneficiaries with SCI. ReWalk develops, manufactures, and markets wearable robotic exoskeletons for individuals with lower limb disabilities. The companys mission is to improve the quality of life for individuals with lower limb disability through innovative robotic technologies.
Customers
growth-positive
ReWalk Robotics Appoints Michael Lawless as Chief Financial Officer
ReWalk Robotics Ltd. has appointed Michael Lawless as Chief Financial Officer. Lawless brings extensive experience in M&A, investor relations, and financial strategy. The company expects Lawless to add value as they approach key milestones and anticipated growth. ReWalk is considering acquiring complementary businesses to supplement organic growth. Lawlesss experience in investor relations will help increase awareness of ReWalks opportunities and strengthen their investor base. The company is well-positioned to fund organic growth and acquisitions due to its strong balance sheet. Lawless previously served as a CFO consultant for Danforth Advisors and held various finance roles at life science and technology companies. In conjunction with his appointment, Lawless will receive 225,000 Restricted Stock Units. The units will vest over time, subject to Lawlesss continued employment with ReWalk.
Management Changes
growth-positive
ReWalk Joins Israeli Technology Innovation Consortium for Human-Robot Interaction
ReWalk Robotics has announced its membership in the Human Robot Interaction (HRI) Consortium, part of the Israel Innovation Authoritys MAGNET incentive program. The program provides grants for R&D collaboration to develop advanced technologies for robots with social capabilities. ReWalk will collaborate with universities to improve the human-exoskeleton interaction and promote wider adoption of the technology. The HRI Consortium is a 3-year project, and ReWalk is one of nine companies participating. The first meeting of the HRI cohort is scheduled for May 2022.
PartnersInvestment
growth-positive
ReWalker Sets Guinness World Record for Climbing a London Skyscraper While Wearing an Exoskeleton
ReWalk Robotics announced that Simon Kindleysides, a paralyzed man, has earned a Guinness World Record by climbing to the top of Londons Leadenhall Building while wearing the companys wearable robotic exoskeleton. Kindleysides previously set a record by walking the London Marathon in the exoskeleton suit. ReWalks CEO congratulated Kindleysides and expressed hope to bring the stairs function of the exoskeleton to the U.S. market. ReWalk Robotics develops and manufactures wearable robotic exoskeletons for individuals with lower limb disabilities.
CustomersExpand
growth-positive
FDA Designates ReWalk's ReBoot Soft Exo-Suit a Breakthrough Device
ReWalk Robotics ReBoot device has been designated a breakthrough device by the FDA. The lightweight orthotic exo-suit is intended to assist ambulatory functions in people with reduced ankle function related to neurological injuries. It works in conjunction with the muscles of the affected leg to improve users gait. The FDA designation is a positive growth impact for ReWalk Robotics.
Customers
growth-positive
ReWalk Robotics Announces $8.0 Million Private Placement Priced At-the-Market
ReWalk Robotics Ltd. has entered into securities purchase agreements with investors to raise $8.0 million through a private placement. The funds will be used for sales, marketing, reimbursement expenses, research and development activities, and general corporate purposes. The private placement is expected to close on or about December 7, 2020.
Investment
growth-positive
ReWalk Robotics Receives Medicare Provider Certification
ReWalk Robotics has been authorized as a Medicare Provider by the Centers for Medicare & Medicaid Services (CMS). This certification allows the company to bill Medicare directly for its ReWalk Personal Exoskeleton for Medicare beneficiaries. The certification follows the issuance of a Healthcare Common Procedure Coding System (HCPCS) Level II Code for the ReWalk 6.0 Exoskeleton system. ReWalk will now pursue in-network status with private insurance companies to expand access to individuals without out-of-network Durable Medical Equipment benefits. The company aims to improve access to its Personal Exoskeleton for the spinal cord injury community.
Customers
growth-positive
ReWalk Robotics announces the Appointment of Randel E. Richner, BSN, MPH to its Board of Directors
ReWalk Robotics has announced the appointment of Randel Richner to its Board of Directors. Richner brings extensive experience in health policy, reimbursement, economics, and data analytics. She has served on various committees and advisory boards related to healthcare policy and has founded a firm that advises the industry on healthcare policy. ReWalk Robotics believes that Richners expertise will benefit the entire industry and help guide government policy for exoskeletons. Richner has a Master of Public Health in Health Policy and Administration and a Bachelor of Science in Nursing. ReWalk Robotics develops and markets wearable robotic exoskeletons for individuals with lower limb disabilities.
Management Changes
growth-positive
In a Giant Step for the Exoskeleton Industry ReWalk Receives Insurance Code for ReWalk Personal Exoskeleton
ReWalk Robotics has been granted a CMS HCPCS Level II code for their ReWalk Personal exoskeleton, marking a significant milestone for the entire exoskeleton industry. The code will facilitate insurance claim submissions and processing, allowing for further coverage and appropriate payment rates with U.S. national, state, and private payors. This development is part of ReWalk Robotics commitment to developing powered solutions for individuals with lower limb disability and making them more accessible. The company has achieved several key milestones in the industry, including earning the first FDA clearance for an exoskeleton and collaborating with the Department of Defense to establish a policy for injured U.S. Veterans to have access to exoskeletons. This announcement signifies progress in the medical exoskeleton industry, moving towards standard coverage rather than case-by-case basis.
Customers
growth-positive
ReWalk Robotics Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ReWalk Robotics Ltd. has entered into definitive agreements with several institutional investors for a registered direct offering. The offering includes the issuance of approximately 4,938,278 ordinary shares at a purchase price of $1.8225 per share. The investors will also receive unregistered warrants to purchase up to 2,469,139 ordinary shares. The gross proceeds from the offering are expected to be approximately $9.0 million. ReWalk intends to use the net proceeds for sales, marketing, and reimbursement expenses, research and development costs, and general corporate purposes. The offering is expected to close on or about July 6, 2020.
Investment
growth-positive
ReWalk Announces Publication of ReStore Powered Exo-Suit Clinical Study Results
ReWalk Robotics has announced the publication of the results of its multi-center clinical study of the ReStore Exo-Suit for stroke rehabilitation. The study examined patient safety and functional walking outcomes in stroke survivors. The findings were published in the Journal of NeuroEngineering and Rehabilitation and showed positive results in terms of safety and improved walking speeds. The ReStore Exo-Suit is a versatile gait therapy solution designed to assist individuals with lower limb disabilities. The study involved five leading rehabilitation institutions in the US. ReWalk Robotics aims to improve patient outcomes post-stroke with its innovative technology.
Customers
growth-positive
ReWalk Robotics Finalizes U.S. Distribution Agreements for Two Additional Neuro Rehabilitation Product Lines
ReWalk Robotics has finalized two separate agreements to distribute additional product lines in the United States market. The company will be the exclusive distributor of the MediTouch Tutor movement biofeedback systems and will also have distribution rights for the MYOLYN MyoCycle Functional Electrical Stimulation (FES) cycles. The addition of these products expands ReWalks portfolio and potentially increases access to new customers. The MediTouch Tutor devices also allow the company to enter the telehealth capable products category. The agreements are expected to launch commercial activities in July 2020.
CustomersPartners
growth-positive
ReWalk Robotics Increases Focus on Telehealth Opportunities
ReWalk Robotics has announced an extension to its collaboration with researchers at Harvard University to develop wearable exosuits for patients with limited mobility. The collaboration, which began in 2016, will now continue until March 2023. The research team will focus on incorporating features that support the increasing demand for telehealthcare, including remote data provision, analysis, and remote physical therapy. ReWalk CEO Larry Jasinski expressed the companys eagerness to see how telehealth technology can be integrated into next-generation exosuits to meet the needs of a mobility-challenged patient population. The collaboration has already resulted in innovations such as ReWalks ReStore system, which received FDA clearance in 2019. The initial funding commitment for the research collaboration will be spread out over an additional nine months.
Partners
growth-positive
Israeli technology is finding a home in the Canadian health system
ReWalk Robotics, an Israeli medical device company, has provided a wearable exoskeleton to Capt. Trevor Greene, a Canadian soldier who was left unable to walk after an attack in Afghanistan. The device, which was connected by neuroscientist Ryan D’Arcy, has been used as part of Greenes therapy and is continuing to be used in clinical research. The use of the ReWalk apparatus in British Columbia could be the first of several Israeli-designed medical devices to be used in the region. The relationship between Israel and British Columbia has led to an exchange of research and communication of best practices.
CustomersPartners
growth-positive
First Paralyzed American Completes a Marathon Using a ReWalk Exoskeleton
ReWalk Robotics announced that a retired Army sergeant became the first paralyzed American to complete a marathon using the companys robotic exoskeleton device. The marathon runner, Theresa Vereline, used the ReWalk Personal 5.0 device to walk the entire 26.2 mile distance of the 2019 New York City Marathon. Vereline, who was paralyzed in 2011, has been using the ReWalk exoskeleton since 2012. ReWalk Robotics received FDA clearance for its devices in 2014 and has a national procurement policy with the U.S. Department of Veterans Affairs. The companys CEO expressed pride in Verelines accomplishment and the inspiration she provides to other veterans and individuals with spinal cord injuries.
Customers
growth-negative
ReWalk plunges after FDA approval and raising $5m
ReWalk Robotics Ltd. has announced the pricing for a $5 million private placement following FDA approval for its new product for stroke rehabilitation. The share price of the company fell 18% after the announcement. The shares in the private placement were priced at $6 per share, 12% below the closing price at the end of Fridays trading. The company plans to use the funds raised to market its newly approved product. The company had only $1.1 million in revenue in the first quarter of 2019, and posted a $4 million loss.
Investment
growth-positive
ReWalk soars after FDA approves stroke therapy system
ReWalk Robotics has received FDA approval for its ReStore Exo-Suit, a product designed for the treatment of stroke victims. The companys share price has jumped 5% and is expected to boost its market cap from $15 million to $41.5 million. ReWalks first product, designed for people with lower limb paralysis, did not generate as much revenue as expected. The ReStore Exo-Suit is aimed at rehabilitation clinics and offers a more affordable and flexible solution compared to previous technologies. ReWalk plans to use its existing sales and service teams to commercialize the product and believes it has potential for use in multiple sclerosis and Parkinsons Disease patients. The companys market cap fell 88% last year, but the approval of the ReStore Exo-Suit could help it recover.
CustomersExpand
growth-positive
ReWalk Receives CE Marking for its Stroke Rehabilitation Suit
ReWalk Robotics has received European regulatory approval for its new exo-suit for stroke rehabilitation called ReStore. The CE mark clears it for sale to rehabilitation clinics in the European Union. ReWalk Robotics has two product lines, with the new ReStore suit designed for stroke victims learning to regain motor skills in their lower limbs. The suit uses software and mechanical mechanisms to prop up the lower body at key joints. ReWalk Robotics is based in Marlborough, Massachusetts and in Yokneam Illit, Israel.
Customers
growth-positive
ReWalk Robotics Appoints Chunlin (Allen) Han to its Board of Directors
ReWalk Robotics Ltd. has appointed Mr. Chunlin (Allen) Han to its board of directors. Mr. Han is an executive director of Liquid Harmony Limited and serves as Head of Investment and Financing for Realcan Pharmaceutical Group Co. Ltd. The appointment was made pursuant to an investment agreement with Timwell Corporation Limited. ReWalk CEO Larry Jasinski expressed gratitude to the departing board member and welcomed Mr. Han to the board.
Management Changes
growth-positive
British Paraplegic Receives ReWalk Exoskeleton Device After Successful Campaign to Walk Again
ReWalk Robotics has delivered a ReWalk Personal 6.0 System to Lucy Dodd, a British childrens social care worker who is paralyzed by a rare spinal condition. The system was delivered following a successful fundraising campaign led by Dodd and supported by the Association for the Independence of Disabled People. The ReWalk exoskeleton will allow Dodd to stand and walk again. The company will provide training and support for Dodd to use the system at home and in her daily life activities. ReWalk Robotics is a leading manufacturer of robotic medical devices for individuals with lower limb disabilities.
Customers
growth-positive
ReWalk Robotics Announces Closing of $4.37 Million Public Offering
ReWalk Robotics has announced the closing and funding of its public offering of 19,000,000 ordinary shares at a price of $0.23 per share. The gross proceeds from the offering are $4.37 million. The company plans to use the net proceeds for sales, marketing, reimbursement expenses, research and development costs, and expansion of its technological platform. The offering was facilitated by H.C. Wainwright & Co. ReWalk Robotics develops wearable robotic exoskeletons for individuals with lower limb disabilities.
InvestmentExpand
growth-positive
Exoskeleton Developer ReWalk Files for FDA Approval
ReWalk Robotics has filed for clearance with the U.S. Food and Drug Administration for its exoskeleton suit for gait rehabilitation of stroke sufferers. The company expects a potential commercial launch of the suit in the U.S. later in the year, depending on FDA approval. ReWalk is also filing for approval in the European Union and plans to make the device available to stroke patients and rehab clinics in Europe by mid-2019. ReWalk previously developed a rigid-frame exoskeleton for people with spinal cord injuries and unveiled the ReStore model in 2017, which allows therapists to adjust treatment to patients needs.
InvestmentExpand
growth-positive
ReWalk Robotics touts first U.S. insurer reimbursement win for exoskeleton devices
ReWalk Robotics announces that health insurer Cigna will review submissions for the use of exoskeleton devices for individuals with spinal cord injuries. This policy change is the first of its kind by a major private insurer in the U.S. and is expected to have an immediate impact on the lives of qualified beneficiaries. ReWalk Robotics CEO, Larry Jasinski, believes that other payors will follow Cignas lead in providing the latest technologies for their members. Earlier this month, ReWalk Robotics reported better-than-expected earnings but missed sales consensus.
Customers
growth-positive
ReWalk Announces Cigna as First Private U.S. Insurer to Adopt National Policy Change for Coverage of Personal Exoskeleton Devices
Cigna Corporation has revised its policy to consider providing coverage for exoskeleton medical devices for persons with spinal cord injury (SCI) on a case-by-case basis. This policy change is the first of its kind by a major private insurer. ReWalk Robotics, the manufacturer of wearable robotic exoskeletons, sees this as a major milestone for healthcare beneficiaries in the United States and expects an immediate impact on the lives of qualified beneficiaries. The National Spinal Cord Injury Statistical Center estimates that there are about 17,700 new spinal cord injury cases each year in the US. ReWalk Robotics has been actively engaging with payors to educate them about the benefits of exoskeleton use, and they anticipate that other payors will follow Cignas lead.
Customers
growth-positive
ReWalk Robotics Announces Closing of $12.1 Million Public Offering
ReWalk Robotics Ltd. has announced the closing of its underwritten public offering, which resulted in aggregate gross proceeds of approximately $12.1 million. The company plans to use the net proceeds for sales, marketing, research and development, and repayment of outstanding debt. The offering was made under an effective registration statement on Form S-1. ReWalk Robotics develops wearable robotic exoskeletons for individuals with lower limb disabilities. The company aims to improve the quality of life for individuals with lower limb disability through the development of robotic technologies.
Investment
growth-positive
United Spinal Association Issues Recommendation for Insurers to Consider Powered Exoskeleton Devices Medically Necessary for Paralyzed Individuals
ReWalk Robotics applauds United Spinal Associations recommendation that health insurance providers consider the use of powered exoskeleton devices as medically necessary for eligible individuals with spinal cord injuries. The recommendation is based on the organizations review of current peer-reviewed medical literature. ReWalk CEO Larry Jasinski expresses excitement about the recommendation and its potential impact on increasing access to life-changing technology. The article also mentions that there is currently one national coverage policy for exoskeleton devices issued by the U.S. Department of Veterans Affairs.
Customers
growth-positive
ReWalk Announces Placement of 500th Exoskeleton System
ReWalk Robotics Ltd. has announced the placement of its 500th robotic exoskeleton medical device. The majority of these devices are used by individuals with spinal cord injuries in their homes and communities, while others are located in rehabilitation centers. The company is focused on expanding insurance coverage of exoskeletons for all persons with spinal cord injury and has helped develop national coverage policies with payers in several countries. To date, 38 different payers in the United States and 39 in Germany have provided positive coverage decisions for ReWalk Personal systems.
CustomersExpand
growth-positive
Robotic exoskeletons: Helping paraplegics walk again
The article discusses a Massachusetts company called ReWalk that produces robotic exoskeletons to help paraplegics walk again. The exoskeletons have gained FDA approval and are seen as a breakthrough in medical technology. However, they are expensive, with ReWalks newest model costing around $100,000. Some insurers still view the exoskeletons as experimental, leading to denials of coverage. The article highlights the positive impact of the exoskeletons on the lives of paralyzed individuals, improving mobility and reducing the risk of dangerous side effects. It also mentions the challenges faced by individuals in obtaining coverage for the exoskeletons from insurance companies. The date of the article is August 12, 2018.
Customers
growth-positive
U.S. Department of Veterans Affairs Expands Access to ReWalk Exoskeletons for Paralyzed Veterans with Revised National Policy
ReWalk Robotics announced that the U.S. Department of Veterans Affairs has issued a revision to its national policy on exoskeleton medical device training and procurement for qualifying Veterans with spinal cord injury. The updated policy expands access to training program locations among the VA network and private rehabilitation centers through the VAs Veterans Choice Program. This policy update is a positive growth impact for ReWalk Robotics as it potentially helps many paralyzed Veterans who seek to walk again and expands the number of training centers available for ReWalk systems. The article discusses the Department of Veterans Affairs, the policy update, and the ReWalk 6.0 system.
CustomersPartners
growth-positive
ReWalk Robotics raises $20m from Hong Kong fund
Israeli medical device company ReWalk Robotics has signed a strategic investment agreement with Timwell Corporation. Timwell will invest $20 million in ReWalk to fund its overall development worldwide and establish its presence in the Chinese market. ReWalk has developed a wearable robotic exoskeleton that helps individuals with spinal cord injuries to walk. Under the agreement, ReWalk and Timwell plan to form a joint venture in China to develop, manufacture, and market ReWalks products. The joint venture will initially focus on the development and commercialization of ReWalks products for stroke patients in rehabilitation, followed by spinal cord injury products. This investment allows ReWalk to expand its launch of the Restore soft suit exoskeleton in the US and Europe to China.
PartnersInvestment
growth-positive
German National Health Insurance Agency Announces Addition of ReWalk 6.0 System to National Medical Device Directory
ReWalk Robotics Ltd. has been listed in the German Medical Device Directory, allowing eligible beneficiaries in Germany to seek procurement of a ReWalk system. This decision by the head office of German statutory health insurance is a significant policy milestone and opens up access to exoskeleton devices for individuals with spinal cord injury. The listing means that ReWalk will be among the medical devices for compensation that can be procured by SHI providers. This decision is expected to have a positive impact on the growth of ReWalk Robotics Ltd.
Customers
growth-negative
ReWalk raises $7.2m in secondary Nasdaq offering
ReWalk Robotics has raised $7.2 million in a financing round, with the funds likely to be used for an upcoming clinical trial for its product for stroke treatment. The companys revenue grew 46% in the first nine months of 2017, but it still reported a loss of $20 million. ReWalk plans to adapt its product for other markets, such as multiple sclerosis and Parkinsons Disease. The market for stroke victims is larger, but the ideal customers for the device are those with strong upper bodies and no cognitive damage. The companys home product for limb paralytics has faced challenges in ease of use and insurance indemnification. Selling to clinics is seen as a simpler business model.
InvestmentExpand
growth-positive
ReWalk Robotics shows off a soft exosuit designed to bring mobility to stroke patients
ReWalk showcased its prototype soft exoskeleton, called Restore, at a robotics event. The device, developed in partnership with Harvards Wyss Institute, uses a motorized pulley system to provide mobility to legs affected by stroke. The unaffected leg has sensors that sync up with the movement of the affected leg. ReWalk funds Harvards research and pays to license the patents for its products. The final version of Restore is expected to be available in the US by the end of next year. The technology also has implications for MS, ALS, and Parkinsons patients, as well as for soldiers carrying additional payloads.
Partners
growth-positive
Portland police officer, paralyzed from waist down, stands for promotion to sergeant
Paul Meyer, a police officer with the Portland Police Bureau, has been promoted to sergeant less than five years after being paralyzed from the waist down in an on-duty accident. Meyer, who has been confined to a wheelchair since the accident, used a ReWalk exoskeleton device to stand and take the oath during the promotion ceremony. The exoskeleton, which is estimated to cost $70,000, was covered by the Portland Fire and Police Disability and Retirement Fund. Meyers promotion is seen as a growth-positive impact on the Portland Police Bureau.
Management Changes
growth-positive
ReWalk Robotics is building a 'soft exoskeleton' to rehabilitate stroke patients
ReWalk Robotics Ltd. is developing a new product called a soft exoskeleton that aims to help people with lower limb disability. The device is designed for patients recovering from a stroke or dealing with mobility impairments caused by old age, MS, or Parkinsons disease. The soft exoskeleton prototype consists of a belt, fanny pack, cables, knee braces, and sensor-laden footplates. ReWalk acquired the initial technology design from the Wyss Institute at Harvard. The company plans to conduct clinical studies in the second half of 2017 and aims to make the device available in 2018, pending FDA approvals. ReWalk will seek distribution through the VA health system and private sector rehab centers. The soft exoskeleton will initially have power sufficient to move the legs for two hours at a stretch.
CustomersExpand
growth-positive
ReWalk Robotics Achieves Milestone of 100 Personal Systems Sold
ReWalk Robotics has announced that it has sold its 100th personal system, indicating growing adoption of exoskeletons for personal use. The company has also sold over 150 systems to rehabilitation centers, which are key to enabling the growth of personal unit sales. ReWalks personal systems are being used by a diverse range of end users across multiple countries. The CEO of ReWalk Robotics, Larry Jasinski, stated that this milestone symbolizes a new era for the company, with more insurers willing to procure and reimburse systems. The technology is evolving rapidly, and there is a growing wealth of clinical evidence outlining the benefits of exoskeletons for users health and well-being. ReWalk Robotics aims to provide this technology to all eligible users.
Customers
growth-positive
ReWalk readies for $147m Nasdaq secondary offering
ReWalk Robotics is revising its shelf prospectus for a debt offering of up to $100 million. Shareholders can also sell 4.4 million shares at a value of $47 million. The company plans to use the funds for general business needs. ReWalk recently secured a $20 million line of credit from Kreos Capital. The company had $17.9 million in cash at the end of 2015. ReWalks market cap is $127 million. The companys shares have had a negative 12.7% return since its IPO in September 2014. ReWalk finished 2015 with $3.7 million in revenue and a $23.1 million net loss. The CEO is Larry Jasinski.
InvestmentPublic Trading
growth-positive
Kreos Capital V Provides $20MM Financing to ReWalk Robotics - ABFJournal
ReWalk Robotics has secured a line of credit of up to $20 million from Kreos Capital V Limited. The company has drawn down an initial tranche of $12 million and can access an additional $8 million subject to certain conditions. The agreement includes interest-only payments for the first 12 months and monthly principal and interest payments thereafter. Kreos Capital V Limited has also been issued a warrant to purchase ordinary shares of ReWalk Robotics. The financing will be used for working capital and market expansion.
Investment
growth-positive
ReWalk shares soar after win with US military
The US Department of Veterans Affairs has issued a national policy for the evaluation, training, and procurement of ReWalk Personal exoskeleton systems for all qualifying veterans. This announcement has caused the share price of ReWalk Robotics Ltd. to double. The policy is exclusive to ReWalk Robotics exoskeleton systems and is the first national coverage policy in the United States for individuals with spinal cord injuries. ReWalk CEO Larry Jasinski believes this policy will substantially improve the health and quality of life for many veterans.
Customers
growth-negative
ReWalk Robotics raises $36m in Nasdaq IPO
ReWalk Robotics Ltd. raised $36 million in its IPO on Nasdaq, falling short of its original goal of $58 million. The companys share price more than doubled on its first day of trading. ReWalk Robotics has developed FDA-approved exoskeletons that enable paraplegics to walk. The company may receive an additional $5.5 million from underwriters. Founded in 2001, the company earned $1.6 million in revenue in 2013 but had a loss of $12.2 million. The device costs $60-70,000. The companys founder, Dr. Amit Goffer, holds a 3.7% stake in ReWalk.
Public TradingInvestment
growth-positive
ReWalk Robotics files for $58m Nasdaq IPO
ReWalk Robotics Ltd., a Yokneam-based company, has filed for an IPO on Nasdaq to raise $58 million. The companys flagship product is a wearable robotic exoskeleton that allows individuals with Spinal Cord Injury (SCI) to stand upright and walk. The product was developed by Dr. Amit Goffer, the company Founder and President. ReWalk recently received FDA approval for its device for home use. The company has marketed the product in hospitals and earned $1.6 million in revenue in 2013. The device costs $60-70,000.
Public TradingInvestment
Lifeward Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 23 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 16 classification IDs that could be used for matching.
Lifeward Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 93/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 513121376 |
| Crunchbase | argo-medical-technologies |
| Phone | +97249590123 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-08-14T00:00:00.000Z |
| Created | 2014-06-12T00:00:00.000Z |
| Status detail | Public on NASDAQ on Sep, 2014; |